此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias

2017年6月28日 更新者：Pfizer

A Phase 1/2 Study Of Bosutinib (Ski-606) In Philadelphia Chromosome Positive Leukemias

This is an open-label, continuous daily dosing, two-part safety and efficacy study of SKI-606 (bosutinib) in Philadelphia chromosome positive leukemias (Ph+). Part 1 is a dose-escalation study in chronic phase Chronic Myelogenous Leukemia (CML) subjects to establish the maximum tolerated dose (MTD) in this subject population. Part 2 has begun after the completion of Part 1 and after a dose has been established for the compound in chronic phase subjects. Part 2 is a study of the the efficacy of 500mg daily oral SKI-606 (bosutinib) in patients with all phases of Ph+ CML and Ph+ Acute Lymphocytic Leukemia (ALL). The protocol will test the hypotheses that oral daily dosing of bosutinib at 500 mg will attain (1) Major Cytogenetic Response (MCyR) in chronic phase CML patients and (2) Overall Hematological Response (OHR) in advanced leukemia patients. Each phase of the disease will be evaluated as a separate cohort.

研究概览

地位

完全的

条件

干预/治疗

研究类型

介入性

注册 (实际的)

571

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 中国
      • Shanghai、中国、200025
        • The Department of Hematology, Ruijin Hospital Affiliated to School of Medicine of Shanghai Jiaotong
    • P.r China
      • Zhejiang、P.r China、中国、310003
        • The First Hospital affiliated to the Medical School of Zhejiang University
    • P.r. China
      • Beijing、P.r. China、中国、100730
        • Peking Union Medical College Hospital of Chinese Academy of Medical Sciences
      • Beijing、P.r. China、中国、100853
        • The Department of Hematology, The Chinese PLA General Hospital
      • Tianjin、P.r. China、中国、300020
        • The Hematology Hospital of Chinese Academy of Medical Sciences
  • 俄罗斯联邦
      • Ekaterinburg、俄罗斯联邦、620102
        • State Healthcare Institution, Sverdlovsk Regional Clinical Hospital
      • Kirov、俄罗斯联邦、610027
        • Kirov Research Institute of Hematology and Blood transfusion of Roszdrav Hematology clinic
      • Moscow、俄罗斯联邦、125167
        • Hematological Research Centre of RAMS
      • Moscow、俄罗斯联邦、129110
        • Moscow regional Clinical Research Institute named after M.F Vladimirsky
      • Rostov-on Don、俄罗斯联邦、344022
        • Rostov State Medical University of Roszdrav
      • Saint Petersburg、俄罗斯联邦、197022
        • Saint Petersburg State Medical University Hematology Department
  • 加拿大
    • Alberta
      • Edmonton、Alberta、加拿大、T6G1Z2
        • Cross Cancer Institute
    • British Columbia
      • Kelowna、British Columbia、加拿大、V1Y 5L3
        • BC Cancer Agency - Cancer Centre for the Southern Interior
    • Manitoba
      • Winnipeg、Manitoba、加拿大、R3E 0V9
        • CancerCare Manitoba
    • Ontario
      • Toronto、Ontario、加拿大、M5G 2M9
        • University Health Network Princess Margaret Hospital
    • Quebec
      • Montreal、Quebec、加拿大、H3T 1E2
        • Sir Mortimer B. Davis, Jewish General Hospital
  • 匈牙利
      • Budapest、匈牙利、1096
        • Fovarosi Onkormanyzat Egyesitett Szent Istvan es Szent Laszlo
  • 南非
      • Bloemfontein、南非、9301
        • University of The Free State
      • Cape Town、南非、7925
        • University of Cape Town
      • Parktown、南非、2193
        • Johannesburg Hospital
      • Soweto、南非、2013
        • Clinical Haematology Unit
  • 印度
    • Tamil Nadu
      • Vellore、Tamil Nadu、印度、632 004
        • Christian medical college
  • 台湾
      • Taipei 100、台湾、10018
        • National Taiwan University Hospital - Section of Hematology-Oncology
  • 哥伦比亚
    • Antioquia
      • Medellin、Antioquia、哥伦比亚、4459000
        • Hospital Pablo Tobon Uribe
    • Cundinamarca
      • Bogota、Cundinamarca、哥伦比亚
        • Fundacion Santa Fe de Bogota
  • 墨西哥
      • Nuevo Leon、墨西哥、64460
        • Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
      • Toluca Estado de Mexico、墨西哥、CP50180
        • Centro Oncologico Estatal ISSEMYM
  • 大韩民国
      • Seoul、大韩民国、137-701
        • The Catholic University of Korea, Seoul St. Mary Hospital
      • Seoul、大韩民国、138736
        • Dept. of Hematology
  • 奥地利
      • Wels、奥地利、4600
        • Klinikum Kreuzschwestern Wels
  • 巴西
      • Curitiba, PR、巴西、CEP: 80060-900
        • Hospital de Clinicas - Universidade Federal do Parana
    • Sao Paulo/sp - Brazil
      • Jardim Paulista、Sao Paulo/sp - Brazil、巴西、CEP: 01401-901
        • Hospital Brigadeiro da Secretaria de Estado da Saude de Sao Paulo
    • Sp - Brazil
      • Santo Andre、Sp - Brazil、巴西、CEP 09060-650
        • Centro de Estudos da Disciplina dr Hematologia da Faculdade de Medicine do ABC
    • Sp Brazil
      • Sao Paulo、Sp Brazil、巴西、05403-000
        • Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo
  • 德国
      • Dresden、德国、01307
        • University Hospital Carl Gustav Carus
      • Hamburg、德国、20246
        • Universitaetsklinikum Hamburg-Eppendorf
      • Hamburg、德国、20246
        • Universitaetsklinikum Hamburg - Eppendorf
      • Magdeburg、德国、39120
        • Universitaetsklinikum Magdeburg A. oe. R.
      • Mainz、德国
        • Universitaetsklinikum Mainz
      • Mainz、德国、55101
        • III Medizinische Klinik und Poliklinik
      • Mainz、德国、55131
        • Klinikum der Johann Gutenberg Universitaet Mainz
      • Mainz、德国、D-55101
        • Universitaet Mainz Iii. Medizinische Klinik Abteilung Fuer Haematologie
      • Mannheim、德国、68169
        • III. Medizinische Klinik
    • RP
      • Mainz、RP、德国、55101
        • Universitaet Mainz
  • 意大利
      • Bologna、意大利、40138
        • AOU-S.Orsola-Malpighi - Universita degli Studi di Bologna
      • Monza、意大利、20900
        • Azienda Ospedaliera San Gerardo
    • Province of Bologna
      • Bologna、Province of Bologna、意大利、40138
        • University of Bologna
    • Torino
      • Orbassano、Torino、意大利、10043
        • Azienda Ospedaliero - Universitaria San Luigi Gonzaga
  • 挪威
    • Norge
      • Trondheim、Norge、挪威、7006
        • Avd. for blodsykdommer
  • 新加坡
      • Singapore、新加坡、169608
        • Singapore General Hospital
  • 智利
      • Temuco、智利
        • Instituto Clinico Oncologico del Sur
  • 澳大利亚
      • Adelaide、澳大利亚、SA 5000
        • Institute of Medical and Veterinary Science
      • Melbourne、澳大利亚、3181
        • Department of Clinical Haematology and Bone Marrow Transplantation
      • Queensland、澳大利亚、4029
        • Royal Brisbane and Women'S Hospital
      • Queensland、澳大利亚、4101
        • Haematology and Oncology Clinics of Australia
    • South Australia
      • Adelaide、South Australia、澳大利亚、5000
        • Royal Adelaide Hospital
  • 瑞典
      • Uppsala、瑞典、75185
        • Akademiska University Hospital
  • 秘鲁
      • Lima、秘鲁、11
        • Hospital Nacional Edgardo Rebagliati Martins
  • 美国
    • California
      • Duarte、California、美国、91010
        • City of Hope National Medical Center
    • Colorado
      • Denver、Colorado、美国、80218
        • Rocky Mountain Cancer Centers
      • Denver、Colorado、美国、80218
        • HealthONE Presbyterian
    • District of Columbia
      • Washington, D.C.、District of Columbia、美国、20007
        • Georgetown University Hospital
    • Georgia
      • Atlanta、Georgia、美国、30322
        • Emory University Hospital
      • Atlanta、Georgia、美国、30322
        • Emory Clinic
      • Atlanta、Georgia、美国、30322
        • Winship Cancer Institute
    • Illinois
      • Niles、Illinois、美国、60714
        • Oncology Specialists, S.C.
    • Indiana
      • Indianapolis、Indiana、美国、46237
        • Indiana Blood and Marrow Transplantation
    • Louisiana
      • Shreveport、Louisiana、美国、71103
        • LSU Health Sciences Center
    • Maryland
      • Baltimore、Maryland、美国、21201
        • University of Maryland
      • Baltimore、Maryland、美国、21201
        • University of Maryland Medical Center
    • New York
      • Buffalo、New York、美国、14263
        • Roswell Park Cancer Institute
      • Hawthorne、New York、美国、10532
        • Hudson Valley Hematology and Oncology Associates
      • Hawthorne、New York、美国、10532
        • Westchester Oncology Hematology Group, P.C.
      • Hawthorne、New York、美国、10532
        • Westchester Oncology Hematology, Group, P.C.
      • New York、New York、美国、10021
        • New York Presbyterian Hospital
      • New York、New York、美国、10065
        • New York Presbyterian Hospital
      • Rochester、New York、美国、14642
        • University of Rochester
      • Rochester、New York、美国、14642
        • University of Rochester Medical Center
      • Rochester、New York、美国、14642
        • University of Rochester Cancer Center Pharmacy
      • Rochester、New York、美国、14642
        • University of Rochester-James P. Wilmot Cancer Center
      • Rochester、New York、美国、14642
        • University of Rochester Medical Center Strong Memorial Hospital - James P. Wilmot Cancer Center
      • Valhalla、New York、美国、10595
        • Westchester Medical Center
    • Pennsylvania
      • Hershey、Pennsylvania、美国、17033-0850
        • Penn State Milton S Hershey Medical Center
    • Texas
      • Houston、Texas、美国、77030
        • The University of Texas MD Anderson Cancer Center
      • Houston、Texas、美国、77030
        • The University Of Texas
      • Houston、Texas、美国、77030-4009
        • MD Anderson Cancer Center
    • Virginia
      • Richmond、Virginia、美国、23298-0157
        • Virginia Commonwealth University
  • 芬兰
      • Helsinki、芬兰、FIN-00029 HUS
        • Biomedicum Helsinki
  • 英国
      • London、英国、W12 0HS
        • Hammersmith Hospital
      • Newcastle Upon Tyne, North East England、英国、NE1 4LP
        • Clinical Research Facility
    • North East England
      • Newcastle Upon Tyne、North East England、英国、NE7 7DN
        • Northern Centre for Cancer Care - The Newcastle Upon Tyne Hospitals - NHS Foundation Trust
      • University upon Tyne、North East England、英国、NE1 7RU
        • School of Clinical and Laboratory Sciences
  • 荷兰
      • Amsterdam、荷兰、1081 HV
        • VU University Medical Center
      • Groningen、荷兰、9700 RB
        • University Medical Center Groningen
      • Groningen、荷兰、9713 GZ
        • Universitair Medisch Centrum Groningen
      • Groningen、荷兰、9713 AP
        • UMCG - Pharmacy
      • The Netherlands、荷兰
        • VUMC
  • 西班牙
      • Madrid、西班牙、28006
        • Hospital Universitario La Princesa
      • Valencia、西班牙、46010
        • Hospital Clinico Universitario de Valencia (CHUV)
    • Catalonia
      • Barcelona、Catalonia、西班牙、08036
        • Hospital Clinic de Barcelona (Hospital Clinic i Provincial)
      • Barcelona、Catalonia、西班牙、08036
        • Hospital Universitari Clínic de Barcelona
  • 阿根廷
      • Buenos Aires、阿根廷、1280
        • Hospital Británico
      • Buenos Aires、阿根廷、1426
        • Instituto Médico Especializado Alexander Fleming
      • Buenos Aires、阿根廷、1425
        • Academia Nacional de Medicina-Instituto de Investigaciones Hematologicas
      • Ciudad Autonoma de Buenos Aires、阿根廷、C1425DQI
        • Clinica del Sol
      • Corrientes、阿根廷、3400
        • Centro Medico S.A.
      • Corrientes、阿根廷、3400
        • Hospital Jose Ramon Vidal
      • Pcia de Buenos Aires、阿根廷、B1629ODT
        • Hospital Universitario Austral
    • Provincia de Buenos Aires
      • La Plata、Provincia de Buenos Aires、阿根廷、1900
        • Hospital Italiano de La Plata
  • 香港
      • Chai Wan、香港
        • Pamela Youde Nethersole Eastern Hosp.
      • Hong Kong、香港
        • Queen Mary Hospital

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Ph+ CML or Ph+ ALL who are primarily refractory to full-dose imatinib (600 mg), have disease progression/relapse while on full-dose imatinib, or are intolerant of any dose of imatinib.
  • At least 3 months post stem cell transplantation
  • Able to take daily oral capsules/tablets reliably

Exclusion Criteria:

  • Subjects with Philadelphia chromosome, and bcr-abl negative CML
  • Overt leptomeningeal leukemia
  • Subjects without evidence of leukemia in bone marrow (extramedullary disease only)

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：不适用
  • 介入模型：单组作业
  • 屏蔽：无（打开标签）

武器和干预

参与者组/臂
干预/治疗
实验性的：SKI-606
药品：Bosutinib

Part 1, starting dose 400 mg oral, daily dosing in the dose-escalation component.

Part 2, 500 mg oral, continuous, daily dosing.

其他名称：
  • SKI-606

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Number of Participants With Dose Limiting Toxicity (DLT)
大体时间：Part 1 Baseline up to Day 28
DLT was defined as any of the following events occurring during the first 28 days of study medication and considered at least possibly-related to study medication: any grade 3 or 4 clinically-relevant non-hematologic toxicity, any clinically-significant grade 2 non-hematologic toxicity that requires 14 days to resolve (to grade 1).
Part 1 Baseline up to Day 28
Maximum Tolerated Dose (MTD)
大体时间：Part 1 Baseline up to Day 28

MTD was defined as highest dose level for which no more than 1 participant in a dose cohort experienced DLT. DLT was defined as any of the following events occurring during the first 28 days of study medication and considered at least possibly-related to study medication: any grade 3 or 4 clinically-relevant non-hematologic toxicity, any clinically-significant grade 2 non-hematologic toxicity that requires 14 days to resolve (to grade 1).

NA = not estimable.
Part 1 Baseline up to Day 28
Maximum Observed Plasma Concentration (Cmax) - Part 1
大体时间：0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
Time to Reach Maximum Observed Plasma Concentration (Tmax) - Part 1
大体时间：0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
Plasma Decay Half-Life (t1/2) - Part 1
大体时间：0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

NA = not estimable.
0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC(0-48)] - Part 1
大体时间：0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
AUC(0-48)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-48).
0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
Area Under the Concentration-Time Curve (AUC) - Part 1
大体时间：0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1

AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.

NA = not estimable.
0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
Apparent Oral Clearance (CL/F) - Part 1
大体时间：0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

NA = not estimable.
0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
Apparent Volume of Distribution (Vz/F) - Part 1
大体时间：0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1
Maximum Observed Plasma Concentration at Steady State (Cmax,ss) - Part 1
大体时间：0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15
Maximum plasma concentration over 24 hours at steady state (ss), on Day 15.
0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15
Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax,ss) - Part 1
大体时间：0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15
Time to reach maximum observed plasma concentration over 24 hours at steady state (ss), on Day 15.
0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15
Plasma Decay Half-Life at Steady State (t1/2,ss) - Part 1
大体时间：0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Plasma decay half-life over 24 hours at steady state (ss), on Day 15 was calculated.
0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15
Area Under the Concentration-Time Curve at Steady State (AUCss) - Part 1
大体时间：0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15
AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. AUC over 24 hours at steady state (ss), on Day 15 was calculated.
0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15
Apparent Oral Clearance at Steady State (CL/F,ss) - Part 1
大体时间：0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Apparent oral clearence over 24 hours at steady state (ss), on Day 15 was calculated.
0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 15
Accumulation Ratio (R)
大体时间：0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 1 and Day 15
R=accumulation ratio (AUCss on Day 15/AUC0-24 on Day 1)
0 (pre-dose), 1, 2, 3, 4, 6, 8, 24 hours post-dose on Day 1 and Day 15
Percentage of Participants With MCyR at Week 24 in Chronic Phase Second-line Imatinib Resistant CML Population - Part 2
大体时间：Week 24
CyR is based on the prevalence of Ph+ cells. Major cytogenetic response was categorized as either CCyR or partial CyR (PCyR). CCyR was achieved when there was 0 percent (%) Ph+ cells from at least 20 metaphases from conventional bone marrow cytogenetics or less than (<) 1% positive cells from at least 200 cells analyzed from fluorescent in situ hybridization (FISH). PCyR was achieved when 1 to 35% Ph+ cells were present.
Week 24

次要结果测量

结果测量
措施说明
大体时间
Percentage of Participants With Major Cytogenetic Response (MCyR) - Part 1
大体时间：Weeks 12, 24, 36, 48 and the end of active treatment phase of Part 1 (Week 52)
Cytogenetic response (CyR) is based on the prevalence of Philadelphia positive (Ph+) cells. Major cytogenetic response was categorized as either complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). CCyR was achieved when there was 0% Ph+ cells from at least 20 metaphases from conventional bone marrow cytogenetics or <1% positive cells from at least 200 cells analyzed from FISH. PCyR was achieved when 1 to 35% Ph+ cells were present.
Weeks 12, 24, 36, 48 and the end of active treatment phase of Part 1 (Week 52)
Phosphorylation Inhibition of Breakpoint Cluster Region-Abelson Kinase (Bcr-Abl) - Part 1
大体时间：Baseline, Weeks 4, 8, 12, 24, 36, 48 and the end of the active treatment phase of Part 1 (Week 52)
bcr-Abl is a protein resulting from the transcription of the Philadelphia chromosome following 9:22 chromosomal translocation, and phosphorylation inhibition of which correlates with inhibition of tumor cell growth.
Baseline, Weeks 4, 8, 12, 24, 36, 48 and the end of the active treatment phase of Part 1 (Week 52)
Phosphorylation Inhibition of Crk Like (CrkL) Protein at Baseline - Part 1
大体时间：0 (pre-dose) on Day 1 (Baseline)
CrkL is a protein, phosphorylation of which has been shown to correlate with CML cell growth; and conversely inhibition of their phosphorylation correlates with inhibition of tumor cell growth. Phosphorylation of CrkL was monitored in whole blood cells, as well as in the cluster of differentiation 3 (CD3+) (T cell), CD19+ (B cell) and CD34+ (blast cell) compartments by using fluorescent activated cell sorter (FACS) flow cytometry.
0 (pre-dose) on Day 1 (Baseline)
Percent Change From Baseline in Phosphorylation Inhibition of Crk Like Protein (CrkL) at Day 1, 8 and 15 - Part 1
大体时间：6 hours post-dose on Day 1, 0 (pre-dose), 6 hours post-dose on Day 8, 15

CrkL is a protein, phosphorylation of which has been shown to correlate with CML cell growth; and conversely inhibition of their phosphorylation correlates with inhibition of tumor cell growth. Phosphorylation of CrkL was monitored in whole blood cells, as well as in the CD3+ (T cell), CD19+ (B cell) and CD34+ (blast cell) compartments by using FACS flow cytometry.

NA = not estimable.
6 hours post-dose on Day 1, 0 (pre-dose), 6 hours post-dose on Day 8, 15
Percentage of Participants With Major Cytogenetic Response (MCyR) in Chronic Phase Second-line and Chronic Phase Third-line CML Population - Part 2
大体时间：Week 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks thereafter up to Year 4 (CP3L) or Year 5 (CP2L)
CyR is based on the prevalence of Ph+ cells. MCyR was categorized as either CCyR or PCyR. CCyR was achieved when there was 0% Ph+ cells from at least 20 metaphases from conventional bone marrow cytogenetics or <1% positive cells from at least 200 cells analyzed from FISH. PCyR was achieved when 1 to 35% Ph+ cells were present.
Week 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks thereafter up to Year 4 (CP3L) or Year 5 (CP2L)
Kaplan-Meier Estimate of Retaining an Attained/Maintained Major Cytogenetic Response (MCyR) at Year 5 in Chronic Phase Second-line CML - Part 2
大体时间：From first MCyR to loss of MCyR or censoring, assessed every 12 weeks up to 2 years and then every 24 weeks thereafter up to Year 5
MCyR was categorized as either CCyR or PCyR. CCyR was achieved when there was 0% Ph+ cells from at least 20 metaphases from conventional bone marrow cytogenetics or <1% positive cells from at least 200 cells analyzed from FISH. PCyR was achieved when 1 to 35% Ph+ cells were present. The Kaplan-Meier probability of retaining an attained/maintained MCyR at Year 5 is reported. Median durations were not reached as of the minimum follow-up. Duration of response in weeks =(date of confirmed loss of first attained response or last valid cytogenetic assessment for those censored - date of first attained response)/7.
From first MCyR to loss of MCyR or censoring, assessed every 12 weeks up to 2 years and then every 24 weeks thereafter up to Year 5
Time to Achieve Major Cytogenetic Response (MCyR) in Chronic Phase Second-line CML for Responders Only - Part 2
大体时间：Week 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks thereafter up to Year 5

MCyR was categorized as either CCyR or PCyR. CCyR was achieved when there was 0% Ph+ cells from at least 20 metaphases from conventional bone marrow cytogenetics or <1% positive cells from at least 200 cells analyzed from FISH. PCyR was achieved when 1 to 35% Ph+ cells were present. Time to MCyR was the interval from the date of first dose of study medication until the first date of achieving a given response.

Time to response in weeks equals (=) (event date minus (-) first dose date plus (+) 1)divided (/)7, where the event date is the non-missing date of the first attained response for responders only.
Week 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks thereafter up to Year 5
Kaplan-Meier Estimate of Maintaining Complete Hematologic Response (CHR) at Year 4 (CP3L and ADV) or Year 5 (CP2L) - Part 2
大体时间：From date of first confirmed CHR to loss of CHR or censoring, assessed at Day 1 and 7 of Week 1, Day 7 of Week 2, 3, 4, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks thereafter up to Year 4 (CP3L and ADV) or Year 5 (CP2L)

Hematologic response: if participants met all of the following criteria of CHR: White Blood Cells equal to or less than (≤) institutional upper limit of normal, no peripheral blood blasts or promyelocytes, myelocytes+metamyelocytes <5% in blood, absolute neutrophil count greater than or equal to (≥) 1.0×10^9 per liter (/L) , platelets ≥100×10^9/L & <450×10^9/L, <20% basophils in blood & no extramedually involvement (including hepato- or splenomegaly), ≤5% BM blasts (ADV only & applicable to CP if BM aspirate was performed). The duration of CHR was defined as the interval from the first date of response until the first date of confirmed loss of response. Duration of response in weeks =(date of confirmed loss of attained response or last valid hematologic assessment for those censored - date of first confirmed response)/7. The Kaplan-Meier estimate of maintaining CHR at the end of minimum follow-up is presented (CP2L: Year 5; CP3L & ADV: Year 4). NA = not estimable.

NA = not estimable.
From date of first confirmed CHR to loss of CHR or censoring, assessed at Day 1 and 7 of Week 1, Day 7 of Week 2, 3, 4, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks thereafter up to Year 4 (CP3L and ADV) or Year 5 (CP2L)
Duration of Complete Hematologic Response (CHR) - Part 2
大体时间：From date of first confirmed CHR to loss of CHR or censoring, assessed at Day 1 and 7 of Week 1, Day 7 of Week 2, 3, 4, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks thereafter up to Year 4 (CP3L and ADV) or Year 5 (CP2L)

Hematologic response: if participants met all of the following criteria of CHR: White Blood Cells equal to or less than (≤) institutional upper limit of normal, no peripheral blood blasts or promyelocytes, myelocytes+metamyelocytes less than (<)5% in blood, absolute neutrophil count greater than or equal to (≥) 1.0×10^9 per liter (/L) , platelets <450×10^9/L, platelets ≥100×10^9/L, <20% basophils in blood and no extramedually involvement (including hepato- or splenomegaly), ≤5% BM blasts (required for ADV only and applicable to CP if BM aspirate was performed). The duration of CHR was defined as the interval from the first date of response until the first date of confirmed loss of response. Duration of response in weeks =(date of confirmed loss of attained response or last valid hematologic assessment for those censored - date of first confirmed response)/7.

NA = not estimable.
From date of first confirmed CHR to loss of CHR or censoring, assessed at Day 1 and 7 of Week 1, Day 7 of Week 2, 3, 4, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks thereafter up to Year 4 (CP3L and ADV) or Year 5 (CP2L)
Time to Achieve Complete Hematologic Response (CHR) for Responders Only - Part 2
大体时间：Day 1 and 7 of Week 1, Day 7 of Week 2, 3, 4, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks thereafter up to Year 4 (CP3L and ADV) or Year 5 (CP2L)
The time to CHR was measured from the date of first dosing to the first date of response. Time to response in weeks = (event date - first dose date plus 1)/7, where the event date is the non-missing date of the first attained response for responders only.
Day 1 and 7 of Week 1, Day 7 of Week 2, 3, 4, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks thereafter up to Year 4 (CP3L and ADV) or Year 5 (CP2L)
Cumulative Incidence of Progression/Death - Part 2
大体时间：Years 1, 2, 3, 4, and 5 (CP2L only)

The cumulative incidence of on-treatment progression or death adjusting for the competing risk of treatment discontinuation without the event. Disease progression was determined by the investigator as the reason for treatment discontinuation and death was due to any cause within 30 days of last dose. Duration in months = (date of PD/death or last valid cytogenetic/hematologic assessment if censored - first dose date)/30.4. 95% confidence intervals were calculated using Gray's method.

NA = not estimable. One year = 12 months.
Years 1, 2, 3, 4, and 5 (CP2L only)
Progression Free Survival (PFS) - Part 2
大体时间：Years 1, 2, 3, 4, and 5 (CP2L only)

PFS was based on Kaplan-Meier method. Disease progression was determined by the investigator as the reason for treatment discontinuation and death was due to any cause within 30 days of last dose. Duration in months = (date of PD/death or last valid cytogenetic/hematologic assessment if censored - first dose date)/30.4.

NA = not estimable. One year = 12 months
Years 1, 2, 3, 4, and 5 (CP2L only)
Kaplan-Meier Estimate of Overall Survival (OS) - Part 2
大体时间：Years 1, 2, 3, 4, and 5 (CP2L only)

OS was based on Kaplan-Meier method. Survival was defined as the time period from the date of first dose of bosutinib to the date of death or date of last contact for those censored.

NA = not estimable. One year = 12 months.
Years 1, 2, 3, 4, and 5 (CP2L only)
Overall Survival (OS) - Part 2
大体时间：Years 1, 2, 3, 4, and 5 (CP2L only)

OS was based on Kaplan-Meier method. Survival was defined as the time period from the date of first dose of bosutinib to the date of death or date of last contact for those censored.

NA = not estimable. One year = 12 months.
Years 1, 2, 3, 4, and 5 (CP2L only)
Percentage of Participants With Confirmed Complete Hematologic Response (CHR) - Part 2
大体时间：Day 1 and 7 of Week 1, Day 7 of Week 2, 3, 4, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks thereafter up to Year 4 (CP3L and ADV) or Year 5 (CP2L)
Hematologic response: if participants met all of the following criteria of CHR: White Blood Cells ≤ institutional upper limit of normal, no peripheral blood blasts or promyelocytes, myelocytes+metamyelocytes <5% in blood, absolute neutrophil count ≥ 1.0×10^9/L , platelets <450×10^9/L, platelets ≥100×10^9/L, <20% basophils in blood and no extramedually involvement (including hepato- or splenomegaly), ≤5% BM blasts (required for ADV only and applicable to CP if BM aspirate was performed).
Day 1 and 7 of Week 1, Day 7 of Week 2, 3, 4, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks thereafter up to Year 4 (CP3L and ADV) or Year 5 (CP2L)
Percentage of Participants With Overall Hematologic Response (OHR) by Week 48 in Advanced Leukemia Population - Part 2
大体时间：Day 1 and 7 of Week 1, Day 7 of Week 2, 3, 4, 8, 12, thereafter assessed every 12 weeks up to 1 year
OHR included CHR, no evidence of leukemia (≤5% bone marrow blasts, no peripheral blood blasts or promyelocytes, <5% myelocytes + metamyelocytes in blood, white blood cells ≤ institutional upper limit of normal, 450x10^9/L > platelets > 20x10^9/L, absolute neutrophil count ≥0.5x10^9/L, <20% basophils in blood, no extramedullary involvement [including liver or spleen]), minor hematologic response (acute lymphoblastic leukemia [ALL] patients only, defined as <15% blasts in marrow & blood, <30% blasts + promyelocytes in marrow & blood, <20% basophils in peripheral blood & no extramedullary disease other than spleen & liver) or return to chronic phase (AP/BP participants, defined as <15% blasts in both peripheral blood &bone marrow, <30% blasts + promyelocytes in both peripheral blood & bone marrow, <20% basophils in both peripheral blood & bone marrow, no extramedullary Involvement other than liver or spleen). Participants had to meet at least 1 criterion.
Day 1 and 7 of Week 1, Day 7 of Week 2, 3, 4, 8, 12, thereafter assessed every 12 weeks up to 1 year
Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
大体时间：Baseline up to follow up visit (30 days after last dose of study treatment)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Baseline up to follow up visit (30 days after last dose of study treatment)
Duration of Potentially Clinically Important (PCI) Adverse Events (AEs)
大体时间：Baseline up to follow-up visit (30 days after last dose of study treatment)

An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. The event did not necessarily have a causal relationship with the treatment. PCI AEs included anemia, alanine aminotranferase (ALT), aspartate aminotransferase (AST), cardiac, diarrhea, edema, effusion, gastrointestinal, hemorrhage, hypersensitivity, hypertension, infection, liver, myelosuppression, nausea, neutropenia, rash, renal, thrombocytopenia, vomiting, and vascular events. Duration of AE was calculated as (stop date minus start date) plus 1 for non-missing and non-partial dates.

NA = not estimable.
Baseline up to follow-up visit (30 days after last dose of study treatment)
Percentage of Participants With Change From Baseline in Laboratory Tests Results
大体时间：Week 1, 2, 3, 4, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks thereafter
Laboratory assessments included urinalysis, complete blood count (CBC), prothrombin time/partial prothromboplastin time (PT/PPT), international normalized ratio (INR), blood chemistry and serum pregnancy test (β-HCG). Parameters of special interest included liver function tests and those related to myelosuppression. Potentially clinically important (PCI) laboratory values were defined as National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) grade 3 or higher. Maximum CTCAE grade, and only participants who shifted to Grade 3/4 on-treatment, are reported.
Week 1, 2, 3, 4, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks thereafter
Percentage of Participants With On-treatment PCI Change From Baseline in Electrocardiogram (ECG) Findings
大体时间：Baseline, 0 (pre-dose), 2, 4, 6 hours on Day 1, 0 (pre-dose), 2, 4, 6, 20-23 hours on Day 21, and end of treatment visit
Criteria for PCI changes in ECG (12-lead) were defined as: no sinus rhythm; PR interval >=220 msec and increase of >=20 msec; QRS interval >=120 msec; QT interval corrected using the Fridericia formula (QTcF) and QT interval corrected using the Bazett formula (QTcB) >500 msec or increase of >60 msec; heart rate <=45 beats per minute (bpm) or >=120 bpm or decrease/increase of >=15 bpm.
Baseline, 0 (pre-dose), 2, 4, 6 hours on Day 1, 0 (pre-dose), 2, 4, 6, 20-23 hours on Day 21, and end of treatment visit
Number of Participants With Change From Baseline in Findings of Chest X-ray
大体时间：Baseline, Week 8, and end of treatment
Number of participants whose chest X-ray results changed (worsened or improved) from the Baseline.
Baseline, Week 8, and end of treatment
Number of Participants Who Received Concomitant Medications for Management of Adverse Events (AEs)
大体时间：Baseline and Weeks 1, 2, 3, 4, 8, 12, then every 12 weeks thereafter until end of treatment, for a mean duration of 28 months
Number of participants taking any non-study medications which were administered from Study Day 1 to 30 days after last dose of study treatment as a management of an AE are reported.
Baseline and Weeks 1, 2, 3, 4, 8, 12, then every 12 weeks thereafter until end of treatment, for a mean duration of 28 months
Number of Participants With Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG-PS)
大体时间：Baseline, Week 1, 2, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks thereafter
ECOG-PS measured on-therapy (time between first dose and last dose date with a 30-day lag) assessed participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction;1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work;2=ambulatory (>50% of waking hrs), capable of all self care, unable to carry out any work activities;3=capable of only limited self care, confined to bed/chair >50% of waking hrs;4=completely disabled, cannot carry on any self care, totally confined to bed/chair;5=dead.
Baseline, Week 1, 2, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks thereafter
Percentage of Participants With Change From Baseline in Physical Examinations and Vital Signs
大体时间：Screening, Baseline, and end of treatment
Percentage of participants with PCI physical examinations and vital signs is reported during therapy and at post therapy. Criteria for PCI change in vital signs: heart rate value of <40 beats per min and value >150 beats per min, systolic blood pressure (SBP) of <80 or >210 millimeter of mercury (mmHg), diastolic blood pressure (DBP) of <40 or >130 mmHg, temperature <32 or >40 degree centigrade, respiratory rate (Resp) of <10 or >50 breaths/min and criteria for PCI change in physical examination: >=10% increase or decrease of body weight in kilogram (kg).
Screening, Baseline, and end of treatment
Percentage of Participants With Change From Baseline in Physical Examinations and Vital Signs and Number of Participants With PCI Values
大体时间：Post-therapy
Percentage of participants with PCI physical examinations and vital signs is reported during therapy and at post therapy. Criteria for PCI change in vital signs: heart rate value of <40 beats per min and value >150 beats per min, SBP of <80 or >210 mmHg, DBP of <40 or >130 mmHg, temperature <32 or >40 degree centigrade, Resp of <10 or >50 breaths/min and criteria for PCI change in physical examination: >=10% increase or decrease of body weight in kg. No Ph+ ALL participants were analyzed post-therapy (N=0). Part 1 safety data were originally presented in 2011 and are included as cumulative data in the Part 2 final safety results.
Post-therapy

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Pfizer

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2006年1月18日

初级完成 (实际的)

2009年9月25日

研究完成 (实际的)

2015年8月6日

研究注册日期

首次提交

2005年12月2日

首先提交符合 QC 标准的

2005年12月2日

首次发布 (估计)

2005年12月5日

研究记录更新

最后更新发布 (实际的)

2017年7月27日

上次提交的符合 QC 标准的更新

2017年6月28日

最后验证

2017年6月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • 3160A4-200
  • B1871006, 3160A4-200-WW
  • 2005-004230-40 (EudraCT编号)
  • B1871006 (其他标识符：Alias Study Number)

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

慢性粒细胞白血病的临床试验

  • Shenzhen Second People's Hospital
    招聘中
    中国 CML 患者停用 TKI (TFR_china)
    白血病 | 骨髓的 | 慢性的 | BCR-ABL (Breakpoint Cluster Region-abelson Murine Leukemia) | 积极的
    中国

Bosutinib的临床试验

搜索类似试验

赞助者和合作者

医疗条件

药物干预

CROs by country

CROs in Slovakia

条件

罕见疾病

药物干预

膳食补充剂

赞助者/合作者

地点

3
订阅